Pre-made Keliximab benchmark antibody (Whole mAb, anti-CD4 therapeutic antibody, Anti-IMD79/OKT4D Antibody) for drug discovery and mechanism of action (MOA) research

Anti-CD4 therapeutic antibody (Pre-made Keliximab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Izokibep has been specifically designed to utilize the strengths of Affibody's technology platform to create a very small protein drug (18 kDa, approximately one eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM, approximately 1000X of a typical IL-17 antibody) and antibody-like half-life due to the strong (KD ~50pM) binding affinity to serum albumin. These features lead to the potential for best-in-class efficacy in a convenient, less frequent and at-home subcutaneous administration.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-881-1mg	1mg	3090
GMP-Bios-INN-881-10mg	10mg	Inquiry
GMP-Bios-INN-881-100mg	100mg	Inquiry
GMP-Bios-INN-881-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Keliximab Biosimilar, Whole Mab, Anti-Cd4 Antibody: Anti-IMD79/OKT4D therapeutic antibody
INN Name	Keliximab
Target	CD4
Format	Whole mAb
Derivation	Chimeric
Species Reactivity	human
CH1 Isotype	IgG1 - lambda
VD LC	IgG1 - lambda
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Biogen, Inc. (Cambridge MA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0